Cytokinetics
CYTK
262 hedge funds and large institutions have $3.83B invested in Cytokinetics in 2023 Q1 according to their latest regulatory filings, with 35 funds opening new positions, 83 increasing their positions, 96 reducing their positions, and 47 closing their positions.
68% more call options, than puts
Call options by funds: $13.4M | Put options by funds: $8M
1.98% more ownership
Funds ownership: 112.35% → 114.33% (+2%)
5% less funds holding
Funds holding: 277 → 262 (-15)
10% less funds holding in top 10
Funds holding in top 10: 10 → 9 (-1)
14% less repeat investments, than reductions
Existing positions increased: 83 | Existing positions reduced: 96
21% less capital invested
Capital invested by funds: $4.88B → $3.83B (-$1.05B)
26% less first-time investments, than exits
New positions opened: 35 | Existing positions closed: 47
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
American Century Companies
Kansas City,
Missouri
|
+$61.1M |
| 2 |
Janus Henderson Group
London,
United Kingdom
|
+$57.1M |
| 3 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$43M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
+$40.1M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$34.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$31.2M |
| 2 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$25.2M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$20.2M |
| 4 |
Morgan Stanley
New York
|
-$18.5M |
| 5 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
-$16.9M |
CYTK Hedge Fund Activity: Q1 2023 in Review
262 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Cytokinetics (CYTK) for Q1 2023, worth a combined $3.83B — down 21% from $4.88B a quarter earlier.
Sellers outnumbered buyers: 47 funds closed out of CYTK and 35 opened new positions — a net loss of 12 holders — while 96 trimmed existing stakes and 83 added.
The largest buyer was American Century Companies, adding an estimated $61.1M. The largest seller was Farallon Capital Management, cutting an estimated $31.2M.
- 262 institutional investors held Cytokinetics (CYTK) as of Q1 2023, down from 277 in Q4 2022.
- Funds reported $3.83B of Cytokinetics stock for Q1 2023, down 21% quarter-over-quarter.
- 35 funds opened new Cytokinetics positions in Q1 2023 and 47 closed out, a net change of -12 holders.
- The largest Cytokinetics buyer in Q1 2023 was American Century Companies, an estimated $61.1M added.
- The largest Cytokinetics seller in Q1 2023 was Farallon Capital Management, an estimated $31.2M sold.
Based on aggregated 13F filings for Q1 2023.